John Perentesis P. MD, FAAP

John Perentesis P. MD, FAAP
Professor/ Division DirectorCollege of Medicine--UCJohn.Perentesis@cchmc.org
CHRF-2372 Mail Location 7015 3333 Burnet Avenue Cincinnati OH 45229
Phone:(513) 636-6090Fax: (513) 636-3549
  • Leukemia Research

Research Description

Dr. Perentesis' clinical research focuses on the development of molecularly targeted therapies for pediatric and adolescent cancer. His laboratory program focuses on complementary studies of leukemia biology and pharmacogenetics of childhood cancer therapy. The laboratory has developed novel recombinant anticancer drugs, and discovery of genes involved in cellular regulation. Dr. Perentesis is also committed to expansion of the zebrafish model system in oncology.

Current Publications

  • Horton TM, Perentesis JP, Gamis AS, Alonzo TA, Gerbing RB, Ballard J, Adlard K, Howard DS, Smith FO, Jenkins G, Kelder A, Schuurhuis GJ, Moscow JAA Phase 2 study of bortezomib combined with either idarubicin/cytarabine or cytarabine/etoposide in children with relapsed, refractory or secondary acute myeloid leukemia: A report from the Children's Oncology Group.Pediatr Blood Cancer 61 1754-60 10/1/2014
  • Gerbing RB, Perentesis JP, Whitlock JA, Taub JW, Horton TM, Gamis AS, Meshinchi S, Loken MR, Razzouk BI, Cooper TM, Alonzo TAAAML0523: A report from the Children's Oncology Group on the efficacy of clofarabine in combination with cytarabine in pediatric patients with recurrent acute myeloid leukemia.Cancer 120 2482-9 8/15/2014
  • Fouladi M, Perentesis JP, Weigel B, Blaney SM, Phillips CL, Leary S, Reid JM, McGovern RM, Ingle AM, Ahern CH, Ames MM, Houghton P, Doyle LAA phase I trial of MK-2206 in children with refractory malignancies: a Children's Oncology Group study.Pediatr Blood Cancer 61 1246-51 7/1/2014
  • Weiss B, Widemann BC, Wolters P, Dombi E, Vinks AA, Cantor A, Korf B, Perentesis J, Gutmann DH, Schorry E, Packer R, Fisher MJSirolimus for non-progressive NF1-associated plexiform neurofibromas: an NF clinical trials consortium phase II study.Pediatr Blood Cancer 61 982-6 6/1/2014
  • Widemann BC, Dombi E, Gillespie A, Wolters PL, Belasco J, Goldman S, Korf BR, Solomon J, Martin S, Salzer W, Fox E, Patronas N, Kieran MW, Perentesis JP, Reddy A, Wright JJ, Kim A, Steinberg SM, Balis FMPhase 2 randomized, flexible crossover, double-blinded, placebo-controlled trial of the farnesyltransferase inhibitor tipifarnib in children and young adults with neurofibromatosis type 1 and progressive plexiform neurofibromas.Neuro Oncol 16 707-18 5/1/2014
  • Meshinchi S, Woods WG, Perentesis J, Horan J, Canner J, Alonzo TA, Franklin J, Freyer DR, Gamis A, Gerbing RB, Lange BJDifferences in outcomes of newly diagnosed acute myeloid leukemia for adolescent/young adult and younger patients: a report from the Children's Oncology Group.Cancer 119 4162-9 12/1/2013
  • Cooper TM, Razzouk BI, Gerbing R, Alonzo TA, Adlard K, Raetz E, Gamis AS, Perentesis J, Whitlock JAPhase I/II trial of clofarabine and cytarabine in children with relapsed/refractory acute lymphoblastic leukemia (AAML0523): a report from the Children's Oncology Group.Pediatr Blood Cancer 60 1141-7 7/1/2013
  • Gamis AS, Alonzo TA, Perentesis JP, Meshinchi S, COG Acute Myeloid Leukemia CommitteeChildren's Oncology Group's 2013 blueprint for research: acute myeloid leukemia.Pediatr Blood Cancer 60 964-71 6/1/2013
  • Freyer DR, Felgenhauer J, Perentesis J, COG Adolescent and Young Adult Oncology Discipline CommitteeChildren's Oncology Group's 2013 blueprint for research: adolescent and young adult oncology.Pediatr Blood Cancer 60 1055-8 6/1/2013
  • Scott JR, Courter JD, Saldaña SN, Widemann BC, Fisher M, Weiss B, Perentesis J, Vinks AAPopulation pharmacokinetics of sirolimus in pediatric patients with neurofibromatosis type 1.Ther Drug Monit 35 332-7 6/1/2013
  • Phillips CL, Davies SM, McMasters R, Absalon M, O'Brien M, Mo J, Broun R, Moscow JA, Smolarek T, Garzon R, Blum W, Schwind S, Marcucci G, Perentesis JPLow dose decitabine in very high risk relapsed or refractory acute myeloid leukaemia in children and young adults.Br J Haematol 161 406-10 5/1/2013
  • Cripe TP, Miller SJ, Ratner N, Patel AV, Eaves D, Jessen WJ, Rizvi TA, Ecsedy JA, Qian MG, Aronow BJ, Perentesis JP, Serra ERas-driven transcriptome analysis identifies aurora kinase A as a potential malignant peripheral nerve sheath tumor therapeutic target.Clin Cancer Res 18 5020-30 9/15/2012

The Ohio State University Comprehensive Cancer Center – Arthur G. James Cancer Hospital and Richard J. Solove Research Institute (OSUCCC – James) 300 W. 10th Ave. Columbus, OH 43210 Phone: 1-800-293-5066 | Email: jamesline@osumc.edu